Navigation Links
Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
Date:6/26/2009

DEERFIELD, Ill., June 26, and OSAKA, Japan, June 27, 2009 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary received on June 26 (U.S. time) a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In recent months, the FDA and Takeda have been in discussions about conducting an additional cardiovascular study for alogliptin.

As previously announced on March 6, 2009, the FDA informed Takeda that, although the alogliptin NDA was filed prior to the release of the December 2008 FDA Guidance titled, "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes," the FDA did not believe that the amount of existing alogliptin clinical data was sufficient to meet certain statistical requirements outlined in that Guidance. The FDA has asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA Guidance.

"Takeda will continue to promote key initiatives in order to realize sustained growth from a medium- to long-term perspective," said Takeda President & CEO, Yasuchika Hasegawa.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its co
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013  An international roster of ... May 18, in Santa Monica, Calif. ... lung-sparing therapies for MPM, a rare form of cancer ... the pleura, the lining of the chest. ... Blood Institute, the 3rd Annual International Symposium on Lung-Sparing ...
(Date:5/24/2013)... 2013  Sinovac Biotech Ltd. (NASDAQ: ... in China , announced that ... Sinovac, obtained the Certificate of Good Manufacturing Practices ... State and Food Administration (CFDA) for its proprietary ... its Changping filing and packaging facility. The GMP ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 ... un destacado desarrollador y fabricante de herramientas de ... diagnosis y tratamiento de la enfermedad vascular periférica ... ensayo ADVISE ( Ad enosine V asodilator ... valuation) II durante la sesión de ensayo clínico ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... SCHAUMBURG, Ill. , Feb. 8 Sagent Pharmaceuticals, ... it has received FDA approval of labetalol hydrochloride (HCl) injection, ... be available in two vial sizes – 100 mg per ...  According to the American Heart Association, more than 70 million ...
... , SAN DIEGO , Feb. ... -based innovator of patient safety solutions that help to eliminate ... $30 million in Series B-1 financing. The financing was ... of the global private equity firm, TPG Capital. Co-leads for ...
Cached Medicine Technology:Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP 2Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP 3PatientSafe Solutions, Inc. Closes $30 Million Financing 2PatientSafe Solutions, Inc. Closes $30 Million Financing 3
(Date:5/24/2013)... Florida (PRWEB) May 24, 2013 KC and ... the Title Sponsors for FreeRide836. Their oldest sons, Kyle and ... and Tracey Russell family and several professional kiteboarders. , KC ... amazing project. "This has miraculously come together such that virtually ... able to participate." , 20 kite boarders will meet at ...
(Date:5/24/2013)... The Mirena IUD lawyers at ... the FDA has received more than 59,229 complaints since 2004 ... intrauterine birth control device known as the Mirena IUD.* , ... by the women “included ‘expulsion,’ where the IUD came out ... according to an ABC News article. “Abdominal pain is also ...
(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...
(Date:5/24/2013)... Gift Card Network members Arjowiggins, Neenah ... card material, are combining forces to increase education ... sustainable gift card substrate. , The goal of ... increase education and usage of these products within ... of carbon footprint and environmental impact while maintaining ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Started in 1982, ... held in Orlando. 2013 marks AMTC’s 31st anniversary. SHINE is ... starting with supermodel Millie Lewis and her daughter, Carey Lewis ... agents, managers, casting directors, and music professionals including the New ... and XP Media. They are kings of Hollywood and Christian ...
Breaking Medicine News(10 mins):Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2
... , MONDAY, Jan. 10 (HealthDay News) -- The H1N1 swine ... create a vaccine that can protect people against multiple strains ... who were infected with the H1N1 virus and recovered had ... wide variety of flu strains. The virus matched typical ...
... MONDAY, Jan. 10 (HealthDay News) -- The bullet that scored ... likely cause some permanent damage, but experts aren,t sure at ... doctors at University Medical Center in Tucson who operated on ... by her ability to follow simple instructions. They ...
... It is well known that pain is a highly subjective ... vary depending on distractions and mood. A paper in the ... a cautionary note on measuring perceived pain in research. ... well-defined symptoms other than pain, but because of the subjectivity ...
... Squamous cell carcinoma (SCC) is a common type of skin ... General Hospital investigated the p53-related proteins p63 and p73 in ... (miRs), and p73. In a model of SCC, they found ... made the cells more sensitive to chemotherapy, highlighting a new ...
... an important role in some antioxidant therapies may not be ... promote atherosclerosis, or clogging of the arteries. ... Thrombosis and Vascular Biology , the finding may give clues ... positive results. The protein, called Nrf2, has ...
... a dramatic change during the 20th century in England and ... liver cirrhosis features in Alcohol and Alcoholism . ... classes in the early part of the century, the pattern ... among the lower social classes by the end of the ...
Cached Medicine News:Health News:People Who Recovered From H1N1 Offer Clues to Better Vaccine 2Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 2Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 3Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 4Health News:Does it hurt? 2Health News:Protein thought to protect against oxidative stress also promotes clogging of arteries 2Health News:Social class and changes in mortality from liver cirrhosis over the 20th Century 2
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
Maxi 14 Hybridization Oven. 14 bottle (35 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 medium bottles, pack of mesh, bottle gripper and d...
... Weight: 10.1 kg, Interior Dimensions (WxDxH): ... Exterior Dimensions (WxDxH): 44.6 x 22.4 x ... conical tubes, 2 - 300 x 35 ... mm bottles or 1 - 240 x ...
... Higher signal intensity ,Smaller slot ... Requires less sample ,Small slot dimensions ... results ,More intense signal generated with ... less time. , Accepts all types of ...
Medicine Products: